Skip to content
2000
Volume 32, Issue 36
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

The impact of microRNA-1301-3p (miR-1301-3p) on various cancer subtypes is noteworthy. However, its specific role within the framework of uterine corpus endometrial carcinoma (UCEC) is yet to be clearly defined.

Objective

The objective of this research was to investigate and clarify the function of miR-1301-3p in relation to UCEC.

Methods

Sample data for our study were sourced from The Cancer Genome Atlas (TCGA). Using various statistical techniques, we assessed the potential of miR-1301-3p as a diagnostic and prognostic indicator, as well as its association with clinical characteristics. Additionally, we conducted an analysis of the genes targeted by miR-1301-3p. The expression levels of miR-1301-3p in uterine corpus endometrial carcinoma (UCEC) cell lines were determined by quantitative real-time PCR (qRT-PCR). Cellular viability and migratory capacity were measured using the CCK8 assay and Transwell migration assays, respectively. Moreover, the expression levels of genes and proteins targeted by miR-1301-3p were identified through dual-luciferase reporter gene assays and Western blot analysis.

Results

Expression patterns of miR-1301-3p varied across cancer subtypes, which were significantly linked to specific histological classifications, achieving statistical significance ( < 0.001). In UCEC, higher miR-1301-3p levels correlated with reduced overall survival ( = 0.012) and progression-free survival ( = 0.016), and it emerged as an independent prognostic marker for UCEC. A comparative analysis revealed significantly higher miR-1301-3p levels in UCEC cell lines compared to normal endometrial epithelial cells. Four and a half LIM domains 1 (FHL1) exhibited a negative correlation with miR-1301-3p levels within UCEC tissue samples. miR-1301-3p was shown to promote UCEC cell proliferation and migration through its binding to the 3'-untranslated region (UTR) of the FHL1 gene, thereby repressing FHL1 expression. Additionally, augmenting FHL1 levels was observed to counteract the enhancing impact of miR-1301-3p on UCEC cells.

Conclusion

miR-1301-3p regulates the proliferation and migration of UCEC cells by interacting with the FHL1 gene. miR-1301-3p may serve as a promising prognostic biomarker in UCEC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673341564241031063856
2024-12-11
2025-12-16

  • From This Site

    /content/journals/cmc/10.2174/0109298673341564241031063856
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HeK. WangT. HuangX. YangZ. WangZ. ZhangS. SuiX. JiangJ. ZhaoL. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.J. Cell. Mol. Med.202327684686310.1111/jcmm.1769736824011
     [Google Scholar]
  2. HeK. LiJ. HuangX. ZhaoW. WangK. WangT. ChenJ. WangZ. YiJ. ZhaoS. ZhaoL. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.Front. Oncol.202313109077910.3389/fonc.2023.109077936776306
     [Google Scholar]
  3. SiegelR.L. MillerK.D. FuchsH.E. JemalA. Cancer Statistics, 2021.CA Cancer J. Clin.202171173310.3322/caac.2165433433946
     [Google Scholar]
  4. BrooksR.A. FlemingG.F. LastraR.R. LeeN.K. MoroneyJ.W. SonC.H. TatebeK. VenerisJ.L. Current recommendations and recent progress in endometrial cancer.CA Cancer J. Clin.201969425827910.3322/caac.2156131074865
     [Google Scholar]
  5. XiaC. DongX. LiH. CaoM. SunD. HeS. YangF. YanX. ZhangS. LiN. ChenW. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants.Chin. Med. J. (Engl.)2022135558459010.1097/CM9.000000000000210835143424
     [Google Scholar]
  6. IslamiF. WardE.M. SungH. CroninK.A. TangkaF.K.L. ShermanR.L. ZhaoJ. AndersonR.N. HenleyS.J. YabroffK.R. JemalA. BenardV.B. Annual report to the nation on the status of cancer, Part 1: National cancer statistics.J. Natl. Cancer Inst.2021113121648166910.1093/jnci/djab13134240195
     [Google Scholar]
  7. WangZ. GuanW. MaY. ZhouX. SongG. WeiJ. WangC. MicroRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β- catenin signaling pathway.BMC Cancer202323166810.1186/s12885‑023‑11113‑937460940
     [Google Scholar]
  8. ZhangH.C. HanY.Y. ZhangX.M. XiaoN. JiangT. ZhuS. WangE.P. ChenC.B. miR-522 facilitates the prosperities of endometrial carcinoma cells by directly binding to monoamine oxidase B.Kaohsiung J. Med. Sci.2019351059860610.1002/kjm2.1210731271496
     [Google Scholar]
  9. ZhouZ. XuY.P. WangL.J. KongY. miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1.Biosci. Rep.2019396BSR2019007710.1042/BSR2019007731085718
     [Google Scholar]
  10. ZhouL. WangW. WangF. YangS. HuJ. LuB. PanZ. MaY. ZhengM. ZhouL. LeiS. SongP. LiuP. LuW. LuY. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma.Mol. Cancer20212015710.1186/s12943‑021‑01352‑433781255
     [Google Scholar]
  11. XiaoY. WangX. DongX. ZhangY. LiuH. RBPJ inhibits the movability of endometrial carcinoma cells by miR-155/NF-κB/ROS pathway.OncoTargets Ther.2019128075808410.2147/OTT.S21251931632061
     [Google Scholar]
  12. ZhuangL. QuH. CongJ. DaiH. LiuX. MiR-181c affects estrogen-dependent endometrial carcinoma cell growth by targeting PTEN.Endocr. J.201966652353310.1507/endocrj.EJ18‑053830971627
     [Google Scholar]
  13. ZhengW.P. MengF.L. WangL.Y. miR-544a stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs.Mol. Cell. Probes20205310157210.1016/j.mcp.2020.10157232525042
     [Google Scholar]
  14. ZierauO. HelleJ. SchadyewS. MorgenrothY. BentlerM. HennigA. ChitturS. TenniswoodM. KretzschmarG. Role of miR-203 in estrogen receptor-mediated signaling in the rat uterus and endometrial carcinoma.J. Cell. Biochem.201811975359537210.1002/jcb.2667529331043
     [Google Scholar]
  15. QiaoD. HeX. YangH. ZhouY. DengX. ChengL. ZhouX. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.Am. J. Otolaryngol.202142210292010.1016/j.amjoto.2021.10292033454555
     [Google Scholar]
  16. LuoD. FanH. MaX. YangC. HeY. GeY. JiangM. XuZ. YangL. miR-1301-3p promotes cell proliferation and facilitates cell cycle progression via targeting SIRT1 in gastric cancer.Front. Oncol.20211166424210.3389/fonc.2021.66424233987098
     [Google Scholar]
  17. DuJ. ZhangS. ZhangX. YangZ. XueS. XuG. ZhengB. ChenC. miR-1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression.Thorac. Cancer202314303032304110.1111/1759‑7714.1509337680006
     [Google Scholar]
  18. XuL. NiN. GaoH. HuP. MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.Oncol. Lett.202121432710.3892/ol.2021.1258933692859
     [Google Scholar]
  19. YuanX. ZhangY. YuZ. Expression and clinical significance of miR-3615 in hepatocellular carcinoma.J. Int. Med. Res.2021491030006052098154710.1177/030006052098154733435769
     [Google Scholar]
  20. LuX. JingL. LiuS. WangH. ChenB. miR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma.Int. J. Endocrinol.2022202211510.1155/2022/500612335719192
     [Google Scholar]
  21. LinZ. HuangW. YiY. LiD. XieZ. LiZ. YeM. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma.Int. J. Gen. Med.2021148541855510.2147/IJGM.S34068334849000
     [Google Scholar]
  22. YiW. ShenH. SunD. XuY. FengY. LiD. WangC. Low expression of long noncoding RNA SLC26A4 antisense RNA 1 is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer.Med. Sci. Monit.202127e93452234880202
     [Google Scholar]
  23. ChenJ. TangH. LiT. JiangK. ZhongH. WuY. HeJ. LiD. LiM. CaiX. Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer.Int. J. Gen. Med.2021143951396010.2147/IJGM.S32640234345183
     [Google Scholar]
  24. HanQ. CuiZ. WangQ. PangF. LiD. WangD. Upregulation of OTX2-AS1 is associated with immune infiltration and predicts prognosis of gastric cancer.Technol. Cancer Res. Treat.2023221533033823115409110.1177/1533033823115409136740995
     [Google Scholar]
  25. LiangW. LuY. PanX. ZengY. ZhengW. LiY. NieY. LiD. WangD. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma.Pharm. Genomics Pers. Med.20221598599810.2147/PGPM.S38490136482943
     [Google Scholar]
  26. YangD. LiuM. JiangJ. LuoY. WangY. ChenH. LiD. WangD. YangZ. ChenH. Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma.Cancers (Basel)20221424622010.3390/cancers1424622036551704
     [Google Scholar]
  27. DingX. WanA. QiX. JiangK. LiuZ. ChenB. ZNF695, a potential prognostic biomarker, correlates with im mune infiltrates in cervical squamous cell carcinoma and endoce rvical adenocarcinoma: Bioinformatic analysis and experimental verification.Curr. Gene Ther.202424544145210.2174/011566523228521624022807124438441026
     [Google Scholar]
  28. HongJ. LinX. HuX. WuX. FangW. A five-gene signature for predicting the prognosis of colorectal cancer.Curr. Gene Ther.202121428028910.2174/156652322066620101215180333045967
     [Google Scholar]
  29. LiuJ. LichtenbergT. HoadleyK.A. PoissonL.M. LazarA.J. CherniackA.D. KovatichA.J. BenzC.C. LevineD.A. LeeA.V. OmbergL. WolfD.M. ShriverC.D. ThorssonV. HuH. Caesar-JohnsonS.J. DemchokJ.A. FelauI. KasapiM. FergusonM.L. HutterC.M. SofiaH.J. TarnuzzerR. WangZ. YangL. ZenklusenJ.C. ZhangJ.J. ChudamaniS. LiuJ. LollaL. NareshR. PihlT. SunQ. WanY. WuY. ChoJ. DeFreitasT. FrazerS. GehlenborgN. GetzG. HeimanD.I. KimJ. LawrenceM.S. LinP. MeierS. NobleM.S. SaksenaG. VoetD. ZhangH. BernardB. ChambweN. DhankaniV. KnijnenburgT. KramerR. LeinonenK. LiuY. MillerM. ReynoldsS. ShmulevichI. ThorssonV. ZhangW. AkbaniR. BroomB.M. HegdeA.M. JuZ. KanchiR.S. KorkutA. LiJ. LiangH. LingS. LiuW. LuY. MillsG.B. NgK-S. RaoA. RyanM. WangJ. WeinsteinJ.N. ZhangJ. AbeshouseA. ArmeniaJ. ChakravartyD. ChatilaW.K. de BruijnI. GaoJ. GrossB.E. HeinsZ.J. KundraR. LaK. LadanyiM. LunaA. NissanM.G. OchoaA. PhillipsS.M. ReznikE. Sanchez-VegaF. SanderC. SchultzN. SheridanR. SumerS.O. SunY. TaylorB.S. WangJ. ZhangH. AnurP. PetoM. SpellmanP. BenzC. StuartJ.M. WongC.K. YauC. HayesD.N. ParkerJ.S. WilkersonM.D. AllyA. BalasundaramM. BowlbyR. BrooksD. CarlsenR. ChuahE. DhallaN. HoltR. JonesS.J.M. KasaianK. LeeD. MaY. MarraM.A. MayoM. MooreR.A. MungallA.J. MungallK. RobertsonA.G. SadeghiS. ScheinJ.E. SipahimalaniP. TamA. ThiessenN. TseK. WongT. BergerA.C. BeroukhimR. CherniackA.D. CibulskisC. GabrielS.B. GaoG.F. HaG. MeyersonM. SchumacherS.E. ShihJ. KucherlapatiM.H. KucherlapatiR.S. BaylinS. CopeL. DanilovaL. BootwallaM.S. LaiP.H. MaglinteD.T. Van Den BergD.J. WeisenbergerD.J. AumanJ.T. BaluS. BodenheimerT. FanC. HoadleyK.A. HoyleA.P. JefferysS.R. JonesC.D. MengS. MieczkowskiP.A. MoseL.E. PerouA.H. PerouC.M. RoachJ. ShiY. SimonsJ.V. SkellyT. SolowayM.G. TanD. VeluvoluU. FanH. HinoueT. LairdP.W. ShenH. ZhouW. BellairM. ChangK. CovingtonK. CreightonC.J. DinhH. DoddapaneniH.V. DonehowerL.A. DrummondJ. GibbsR.A. GlennR. HaleW. HanY. HuJ. KorchinaV. LeeS. LewisL. LiW. LiuX. MorganM. MortonD. MuznyD. SantibanezJ. ShethM. ShinbroE. WangL. WangM. WheelerD.A. XiL. ZhaoF. HessJ. AppelbaumE.L. BaileyM. CordesM.G. DingL. FronickC.C. FultonL.A. FultonR.S. KandothC. MardisE.R. McLellanM.D. MillerC.A. SchmidtH.K. WilsonR.K. CrainD. CurleyE. GardnerJ. LauK. MalleryD. MorrisS. PaulauskisJ. PennyR. SheltonC. SheltonT. ShermanM. ThompsonE. YenaP. BowenJ. Gastier-FosterJ.M. GerkenM. LeraasK.M. LichtenbergT.M. RamirezN.C. WiseL. ZmudaE. CorcoranN. CostelloT. HovensC. CarvalhoA.L. de CarvalhoA.C. FregnaniJ.H. Longatto-FilhoA. ReisR.M. Scapulatempo-NetoC. SilveiraH.C.S. VidalD.O. BurnetteA. EschbacherJ. HermesB. NossA. SinghR. AndersonM.L. CastroP.D. IttmannM. HuntsmanD. KohlB. LeX. ThorpR. AndryC. DuffyE.R. LyadovV. PaklinaO. SetdikovaG. ShabuninA. TavobilovM. McPhersonC. WarnickR. BerkowitzR. CramerD. FeltmateC. HorowitzN. KibelA. MutoM. RautC.P. MalykhA. Barnholtz-SloanJ.S. BarrettW. DevineK. FulopJ. OstromQ.T. ShimmelK. WolinskyY. SloanA.E. De RoseA. GiulianteF. GoodmanM. KarlanB.Y. HagedornC.H. EckmanJ. HarrJ. MyersJ. TuckerK. ZachL.A. DeyarminB. HuH. KvecherL. LarsonC. MuralR.J. SomiariS. VichaA. ZelinkaT. BennettJ. IacoccaM. RabenoB. SwansonP. LatourM. LacombeL. TêtuB. BergeronA. McGrawM. StaugaitisS.M. ChabotJ. HibshooshH. SepulvedaA. SuT. WangT. PotapovaO. VoroninaO. DesjardinsL. MarianiO. Roman-RomanS. SastreX. SternM-H. ChengF. SignorettiS. BerchuckA. BignerD. LippE. MarksJ. McCallS. McLendonR. SecordA. SharpA. BeheraM. BratD.J. ChenA. DelmanK. ForceS. KhuriF. MaglioccaK. MaithelS. OlsonJ.J. OwonikokoT. PickensA. RamalingamS. ShinD.M. SicaG. Van MeirE.G. ZhangH. EijckenboomW. GillisA. KorpershoekE. LooijengaL. OosterhuisW. StoopH. van KesselK.E. ZwarthoffE.C. CalatozzoloC. CuppiniL. CuzzubboS. DiMecoF. FinocchiaroG. MatteiL. PerinA. PolloB. ChenC. HouckJ. LohavanichbutrP. HartmannA. StoehrC. StoehrR. TaubertH. WachS. WullichB. KyclerW. MurawaD. WiznerowiczM. ChungK. EdenfieldW.J. MartinJ. BaudinE. BubleyG. BuenoR. De RienzoA. RichardsW.G. KalkanisS. MikkelsenT. NoushmehrH. ScarpaceL. GirardN. AymerichM. CampoE. GinéE. GuillermoA.L. Van BangN. HanhP.T. PhuB.D. TangY. ColmanH. EvasonK. DottinoP.R. MartignettiJ.A. GabraH. JuhlH. AkeredoluT. StepaS. HoonD. AhnK. KangK.J. BeuschleinF. BreggiaA. BirrerM. BellD. BoradM. BryceA.H. CastleE. ChandanV. ChevilleJ. CoplandJ.A. FarnellM. FlotteT. GiamaN. HoT. KendrickM. KocherJ-P. KoppK. MoserC. NagorneyD. O’BrienD. O’NeillB.P. PatelT. PetersenG. QueF. RiveraM. RobertsL. SmallridgeR. SmyrkT. StantonM. ThompsonR.H. TorbensonM. YangJ.D. ZhangL. BrimoF. AjaniJ.A. Angulo GonzalezA.M. BehrensC. BondarukJ. BroaddusR. CzerniakB. EsmaeliB. FujimotoJ. GershenwaldJ. GuoC. LazarA.J. LogothetisC. Meric-BernstamF. MoranC. RamondettaL. RiceD. SoodA. TamboliP. ThompsonT. TroncosoP. TsaoA. WistubaI. CarterC. HayduL. HerseyP. JakrotV. KakavandH. KeffordR. LeeK. LongG. MannG. QuinnM. SawR. ScolyerR. ShannonK. SpillaneA. StretchJ. SynottM. ThompsonJ. WilmottJ. Al-AhmadieH. ChanT.A. GhosseinR. GopalanA. LevineD.A. ReuterV. SingerS. SinghB. TienN.V. BroudyT. MirsaidiC. NairP. DrwiegaP. MillerJ. SmithJ. ZarenH. ParkJ-W. HungN.P. KebebewE. LinehanW.M. MetwalliA.R. PacakK. PintoP.A. SchiffmanM. SchmidtL.S. VockeC.D. WentzensenN. WorrellR. YangH. MoncrieffM. GoparajuC. MelamedJ. PassH. BotnariucN. CaramanI. CernatM. ChemencedjiI. ClipcaA. DorucS. GorincioiG. MuraS. PirtacM. StanculI. TcaciucD. AlbertM. AlexopoulouI. ArnaoutA. BartlettJ. EngelJ. GilbertS. ParfittJ. SekhonH. ThomasG. RasslD.M. RintoulR.C. BifulcoC. TamakawaR. UrbaW. HaywardN. TimmersH. AntenucciA. FaccioloF. GraziG. MarinoM. MerolaR. de KrijgerR. Gimenez-RoqueploA-P. PichéA. ChevalierS. McKercherG. BirsoyK. BarnettG. BrewerC. FarverC. NaskaT. PennellN.A. RaymondD. SchileroC. SmolenskiK. WilliamsF. MorrisonC. BorgiaJ.A. LiptayM.J. PoolM. SederC.W. JunkerK. OmbergL. DinkinM. ManikhasG. AlvaroD. BragazziM.C. CardinaleV. CarpinoG. GaudioE. CheslaD. CottinghamS. DubinaM. MoiseenkoF. DhanasekaranR. BeckerK-F. JanssenK-P. Slotta-HuspeninaJ. Abdel-RahmanM.H. AzizD. BellS. CebullaC.M. DavisA. DuellR. ElderJ.B. HiltyJ. KumarB. LangJ. LehmanN.L. MandtR. NguyenP. PilarskiR. RaiK. SchoenfieldL. SenecalK. WakelyP. HansenP. LechanR. PowersJ. TischlerA. GrizzleW.E. SextonK.C. KastlA. HendersonJ. PortenS. WaldmannJ. FassnachtM. AsaS.L. SchadendorfD. CouceM. GraefenM. HulandH. SauterG. SchlommT. SimonR. TennstedtP. OlabodeO. NelsonM. BatheO. CarrollP.R. ChanJ.M. DisaiaP. GlennP. KelleyR.K. LandenC.N. PhillipsJ. PradosM. SimkoJ. Smith-McCuneK. VandenBergS. RogginK. FehrenbachA. KendlerA. SifriS. SteeleR. JimenoA. CareyF. ForgieI. MannelliM. CarneyM. HernandezB. CamposB. Herold-MendeC. JungkC. UnterbergA. von DeimlingA. BosslerA. GalbraithJ. JacobusL. KnudsonM. KnutsonT. MaD. MilhemM. SigmundR. GodwinA.K. MadanR. RosenthalH.G. AdebamowoC. AdebamowoS.N. BoussioutasA. BeerD. GiordanoT. Mes-MassonA-M. SaadF. BocklageT. LandrumL. MannelR. MooreK. MoxleyK. PostierR. WalkerJ. ZunaR. FeldmanM. ValdiviesoF. DhirR. LuketichJ. Mora PineroE.M. Quintero-AguiloM. CarlottiC.G. Dos SantosJ.S. KempR. SankarankutyA. TirapelliD. CattoJ. AgnewK. SwisherE. CreaneyJ. RobinsonB. ShelleyC.S. GodwinE.M. KendallS. ShipmanC. BradfordC. CareyT. HaddadA. MoyerJ. PetersonL. PrinceM. RozekL. WolfG. BowmanR. FongK.M. YangI. KorstR. RathmellW.K. Fantacone-CampbellJ.L. HookeJ.A. KovatichA.J. ShriverC.D. DiPersioJ. DrakeB. GovindanR. HeathS. LeyT. Van TineB. WesterveltP. RubinM.A. LeeJ.I. AredesN.D. MariamidzeA. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics.Cell20181732400416.e1110.1016/j.cell.2018.02.05229625055
     [Google Scholar]
  30. AgarwalV. BellG.W. NamJ.W. BartelD.P. Predicting effective microRNA target sites in mammalian mRNAs.eLife20154e0500510.7554/eLife.0500526267216
     [Google Scholar]
  31. ChiangH.R. SchoenfeldL.W. RubyJ.G. AuyeungV.C. SpiesN. BaekD. JohnstonW.K. RussC. LuoS. BabiarzJ.E. BlellochR. SchrothG.P. NusbaumC. BartelD.P. Mammalian microRNAs: Experimental evaluation of novel and previously annotated genes.Genes Dev.20102410992100910.1101/gad.188471020413612
     [Google Scholar]
  32. LiuW. WangX. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data.Genome Biol.20192011810.1186/s13059‑019‑1629‑z30670076
     [Google Scholar]
  33. KrekA. GrünD. PoyM.N. WolfR. RosenbergL. EpsteinE.J. MacMenaminP. da PiedadeI. GunsalusK.C. StoffelM. RajewskyN. Combinatorial microRNA target predictions.Nat. Genet.200537549550010.1038/ng153615806104
     [Google Scholar]
  34. ZhangY. ShengH. FuY. ChenL. Transcription factor FOXA1 facilitates glycolysis and proliferation of lung adenocarcinoma via activation of TEX19.Mol. Biotechnol.20246682144215410.1007/s12033‑023‑00848‑237606876
     [Google Scholar]
  35. LinM. SongD. ZhangS. LiP. Dysregulation of miR-638 in diabetic nephropathy and its role in inflammatory response.Diabetol. Metab. Syndr.202113112210.1186/s13098‑021‑00744‑234715911
     [Google Scholar]
  36. PanH. LiuQ. ZhangF. WangX. WangS. ShiX. High STK40 expression as an independent prognostic biomarker and correlated with immune infiltrates in low- grade gliomas.Int. J. Gen. Med.2021146389640010.2147/IJGM.S33582134675607
     [Google Scholar]
  37. LiuX. ZhangY. WangZ. LiuL. ZhangG. LiJ. RenZ. DongZ. YuZ. PRRC2A promotes hepatocellular carcinoma progression and associates with immune infiltration.J. Hepatocell. Carcinoma202181495151110.2147/JHC.S33711134881207
     [Google Scholar]
  38. SatoK. MiyamotoM. TakanoM. TsudaH. MicroRNA-21 expression in cancer cells is an independent biomarker of progression-free survival of endometrioid endometrial carcinoma.Virchows Arch.2021479588389110.1007/s00428‑021‑03171‑w34331128
     [Google Scholar]
  39. MosaadH. AbdelrahmanA. AbdullatifA. LashinM. RamadanM. El-AzonyA. HussienM. MIR-379-5p expression in endometrial cancer and its correlation with ROR1 expression.Asian Pac. J. Cancer Prev.202324123924810.31557/APJCP.2023.24.1.23936708573
     [Google Scholar]
  40. ZhangJ. ZhangD. YanX. JiangF. The expression level and prognostic value of microRNA-15a-5p in endometrial carcinoma.Transl. Cancer Res.202110114838484410.21037/tcr‑21‑207935116336
     [Google Scholar]
  41. GengA. LuoL. RenF. ZhangL. ZhouH. GaoX. miR-29a-3p inhibits endometrial cancer cell proliferation, migration and invasion by targeting VEGFA/CD C42/PAK1.BMC Cancer202121184310.1186/s12885‑021‑08506‑z34289832
     [Google Scholar]
  42. YangL.J. GaoL. GuoY.N. LiangZ.Q. LiD.M. TangY.L. LiuY.H. GaoW.J. ZengJ.J. ShiL. WeiK.L. ChenG. Upregulation of microRNA miR-141-3p and its prospective targets in endometrial carcinoma: A comprehensive study.Bioengineered20211212941295610.1080/21655979.2021.194311134180758
     [Google Scholar]
  43. WuX. HanY. LiuF. RuanL. Downregulations of miR-449a and miR-145-5p act as prognostic biomarkers for endometrial cancer.J. Comput. Biol.202027583484410.1089/cmb.2019.021531513434
     [Google Scholar]
  44. SongX.L. HuangB. ZhouB.W. WangC. LiaoZ.W. YuY. ZhaoS.C. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3β.Biomed. Pharmacother.99369374201810.1016/j.biopha.2018.01.08629358129
     [Google Scholar]
  45. PengX. YanB. ShenY. MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.Breast Cancer201825674275210.1007/s12282‑018‑0881‑529951881
     [Google Scholar]
  46. LiuY. WangC. ChengP. ZhangS. ZhouW. XuY. XuH. JiG. FHL1 inhibits the progression of colorectal cancer by regulating the Wnt/β-catenin signaling pathway.J. Cancer202112175345535410.7150/jca.6054334335951
     [Google Scholar]
  47. XuY. LiuZ. GuoK. Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer.Mol. Cell. Biochem.20123631-2939910.1007/s11010‑011‑1161‑222143536
     [Google Scholar]
  48. NiuC. LiangC. GuoJ. ChengL. ZhangH. QinX. ZhangQ. DingL. YuanB. XuX. LiJ. LinJ. YeQ. Downregulation and growth inhibitory role of FHL1 in lung cancer.Int. J. Cancer2012130112549255610.1002/ijc.2625921702045
     [Google Scholar]
  49. ZhangJ. LiH. GuoM. ZhangJ. ZhangG. SunN. FengY. CuiW. XuF. FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma.Immunotherapy202315423525210.2217/imt‑2022‑019536695131
     [Google Scholar]
  50. LiS.Z. HuY.Y. ZhaoJ.L. ZangJ. FeiZ. HanH. QinH.Y. Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling.Oncol. Lett.20201963781378810.3892/ol.2020.1147632382330
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673341564241031063856
Loading
FHL1 Inhibition by miR-1301-3p Promotes Uterine Corpus Endometrial Carcinoma Cell Proliferation and Migration: A Prognostic Insight
Curr. Med. Chem. 32, 8118 (2025); https://doi.org/10.2174/0109298673341564241031063856
/content/journals/cmc/10.2174/0109298673341564241031063856
/content/journals/cmc/10.2174/0109298673341564241031063856
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): bioinformatics; biomarker; FHL1; microRNA-1301-3p; prognosis; uterine corpus endometrial carcinoma (UCEC)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test